VRTX Price Prediction Next Week
Based on the provided data and recent market activity, here's a comprehensive analysis for VRTX's price prediction for next week:
Technical Analysis
The technical indicators show:
- RSI at 58.55 indicates neutral momentum, not overbought or oversold
- MACD at -1.62 suggests slight bearish momentum
- Current price is below the 200-day SMA (457.85), indicating a bearish trend
- Fibonacci levels show key resistance at 438.58 and support at 403.71
News Sentiment Analysis
- Morgan Stanley maintains positive outlook on VRTX, including it among their recommended stocks for earnings season
- Recent earnings forecasts project $4.00 EPS, showing a 4.76% decline year-over-year
- Strong pipeline developments in cystic fibrosis treatments and expansion into new therapeutic areas support long-term growth
- The company's Q4 revenue is expected at $2.77 billion, showing 10.18% growth year-over-year
Price Prediction for Next Week Based on technical and fundamental factors:
Bullish Scenario (30% probability):
- Target: $438.58 (Fibonacci R1)
- Drivers: Strong earnings beat, positive pipeline updates
Bearish Scenario (45% probability):
- Target: $403.71 (Fibonacci S1)
- Drivers: Earnings miss, broader market weakness
Consolidation Scenario (25% probability):
- Range: $414-422 (around Fibonacci pivot)
- Drivers: In-line earnings, no major catalysts
Recommendation Given the current technical weakness and upcoming earnings uncertainty, a SELL recommendation is warranted at current levels. Optimal entry point for new positions would be around $403-405 support level.
VRTX Similar Chart Price Prediction
The price of VRTX is predicted to go up 0.14%, based on the high correlation periods with AG. The similarity of these two price pattern on the periods is 97.53%.
VRTX
AG
Up: 0.14%Similarity: 97.53%
VRTX Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
VRTX Price Forecast($)
Potential Return(%)
2025
405.050
-0.510
2026
480.000
17.900
2027
350.000
-13.740
2028
600.000
47.380
2029
650.000
61.490
2030
700.000
73.920
What is VRTX stock price prediction 2025 ?
What is VRTX stock price prediction 2026 ?
What is VRTX stock price prediction 2027 ?
What is VRTX stock price prediction 2028 ?
What is VRTX stock price prediction 2029 ?
What is VRTX stock price prediction 2030 ?
VRTX Revenue Forecast
VRTX EPS Forecast
VRTX FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
VRTX VS S&P500
The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.
Vertex's leading drug candidates were mostly discovered in-house, lending credibility to its drug-discovery technology and potential to generate additional pipeline candidates.
Vertex's combination therapies have lengthy patents, protecting the profitable cystic fibrosis portfolio from generics.
VRTX Analyst's Forecast
Joon Lee
Truist Securities
Strong Buy
Price Target
$550 → $460
Upside
+13.5%
Truist analyst Joon Lee lowered the firm's price target on Vertex Pharmaceuticals to $460 from $550 and keeps a Buy rating on the shares. The firm moderates its view of the odds of success of suzetrigine in chronic pain to 30% from 60% after "disappointing" Phase 2 results in lumbosacral radiculopathy. The early approval of vanza triple, or Alyftrek, is "positive, but was largely expected," adds the analyst, who sees upside from pipeline updates in 2025.
Jessica Fye
JP Morgan
Buy
Price Target
$503 → $500
Upside
+23.37%
Gena Wang
Barclays
Hold
Price Target
$509 → $418
Upside
+5.22%